Spyre Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Spyre Therapeutics

01/03/2024 12:04

* Spyre Therapeutics Inc  SYRE.OQ   SYRE.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Spyre Therapeutics Inc
is for
a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 13.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $31.50​, above​ its last closing price
of $27.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.52       -0.78      -4.05     Missed  -416.4
 Sep. 30 2023  -0.68       -0.84      -9.34     Missed  -1,005
                                                        .3
 Jun. 30 2023  -4.50       -4.50      -41.50    Missed  -822.2
                                                        ​
 Mar. 31 2023  -4.75       -4.50      -5.00     Missed  -11.1
 ​​Dec.        -5.04       -5.00      -4.50     Beat    10
 31 2022                                                
 Sep. 30 2022  -5.79       -5.80      -4.75     Beat    18.1​
 Jun. 30 2022  -7.71       -7.79      -6.75     Beat    13.4
 Mar. 31 2022  -8.32       -8.42      -9.25     Missed  -9.9
 This summary was machine generated March 1 at 12:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)